- Home
- FATE vs SEER Comparison
FATE vs SEER Comparison
Compare FATE & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- SEER
- Stock Information
- Founded
- FATE 2007
- SEER 2017
- Country
- FATE United States
- SEER United States
- Employees
- FATE N/A
- SEER N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- SEER Medicinal Chemicals and Botanical Products
- Sector
- FATE Health Care
- SEER Health Care
- Exchange
- FATE Nasdaq
- SEER Nasdaq
- Market Cap
- FATE 108.2M
- SEER 132.4M
- IPO Year
- FATE 2013
- SEER 2020
- Fundamental
- Price
- FATE $0.94
- SEER $1.97
- Analyst Decision
- FATE Hold
- SEER Hold
- Analyst Count
- FATE 9
- SEER 1
- Target Price
- FATE $5.50
- SEER $3.00
- AVG Volume (30 Days)
- FATE 3.4M
- SEER 298.1K
- Earning Date
- FATE 03-05-2025
- SEER 05-07-2025
- Dividend Yield
- FATE N/A
- SEER N/A
- EPS Growth
- FATE N/A
- SEER N/A
- EPS
- FATE N/A
- SEER N/A
- Revenue
- FATE $13,631,000.00
- SEER $14,170,000.00
- Revenue This Year
- FATE N/A
- SEER $29.77
- Revenue Next Year
- FATE N/A
- SEER $47.98
- P/E Ratio
- FATE N/A
- SEER N/A
- Revenue Growth
- FATE N/A
- SEER N/A
- 52 Week Low
- FATE $0.87
- SEER $1.56
- 52 Week High
- FATE $7.70
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- FATE 37.74
- SEER 33.59
- Support Level
- FATE $0.87
- SEER $1.88
- Resistance Level
- FATE $1.03
- SEER $2.37
- Average True Range (ATR)
- FATE 0.12
- SEER 0.11
- MACD
- FATE -0.01
- SEER -0.02
- Stochastic Oscillator
- FATE 13.12
- SEER 19.19
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.